Source:http://linkedlifedata.com/resource/pubmed/id/20962048
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2010-11-24
|
pubmed:abstractText |
After the discovery of ghrelin, we attempted to generate ghrelin gene transgenic (Tg) mice. These animals, however, produced only des-acyl ghrelin, which lacked the n-octanoyl modification at Ser(3) necessary to manifest ghrelin activity. Because the mechanism for acyl-modification of ghrelin had been unclear until the recent identification of GOAT (ghrelin O-acyltransferase), it had been difficult to generate Tg mice overexpressing ghrelin using standard procedures. Therefore, we planned to generate Tg mice overexpressing a ghrelin analog, which possessed ghrelin-like activity in the absence of acylation at Ser(3) and could be synthesized in vivo. As the replacement of Ser(3) of ghrelin with Trp(3) (Trp(3)-ghrelin) preserves a low level of ghrelin activity and Trp(3)-ghrelin can be synthesized in vivo, we generated mice overexpressing Trp(3)-ghrelin by using the hSAP (human serum-amyloid-P) promoter. Plasma Trp(3)-ghrelin concentrations in the Tg mice were approximately 85-fold higher than plasma ghrelin concentrations in non-Tg littermates. Because Trp(3)-ghrelin is approximately 1/10-1/20 less potent than ghrelin in vivo, plasma Trp(3)-ghrelin concentrations in Tg mice were calculated to have an activity approximately 6-fold greater than that of acylated ghrelin seen in non-Tg mice (85-fold x 1/10-1/20). Tg mice exhibited a normal growth and glucose metabolism in their early life stage. However, 1-yr-old Tg mice demonstrated impaired glucose tolerance and reduced insulin sensitivity. This model will be useful to evaluate the long-term effects of ghrelin or ghrelin analogs. In addition, this technique may be a useful method to generate gain-of-activity models for hormones that require posttranscriptional modifications.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1945-7170
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
151
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5935-40
|
pubmed:meshHeading |
pubmed-meshheading:20962048-Animals,
pubmed-meshheading:20962048-Dose-Response Relationship, Drug,
pubmed-meshheading:20962048-Eating,
pubmed-meshheading:20962048-Gene Expression Regulation,
pubmed-meshheading:20962048-Ghrelin,
pubmed-meshheading:20962048-Glucose Intolerance,
pubmed-meshheading:20962048-Growth Hormone,
pubmed-meshheading:20962048-Insulin Resistance,
pubmed-meshheading:20962048-Male,
pubmed-meshheading:20962048-Mice,
pubmed-meshheading:20962048-Mice, Inbred C57BL,
pubmed-meshheading:20962048-Mice, Transgenic
|
pubmed:year |
2010
|
pubmed:articleTitle |
Generation of transgenic mice overexpressing a ghrelin analog.
|
pubmed:affiliation |
Department of Endocrinology and Metabolism, Kyoto University Graduate School of Medicine, Kyoto, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|